Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-09-12
2006-09-12
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
07105573
ABSTRACT:
Insulin sensitivity increasing substances (ISIS), including but not limited to D-chiro-inositol, thiazolidinedione and derivatives, and biguanides, are useful in the treatment of hair loss and other disorders of the pilosebaceous apparatus (hirsutism, acne, etc.) associated with conditions of excess insulin and/or insulin resistance. The treatment comprises administering to a mammal, such as a human, at least one ISIS either alone or in combination with at least one agent, such as an androgen receptor blocker (ARB) and/or a steroid enzyme inhibitor or inducer (STI). Additionally, an activity enhancing agent may be included for topical administration.
REFERENCES:
patent: 4684635 (1987-08-01), Orentreich et al.
patent: 5043162 (1991-08-01), Trager
patent: 5091596 (1992-02-01), Kennington et al.
patent: 5124360 (1992-06-01), Larner et al.
patent: 5292747 (1994-03-01), Davis et al.
patent: 5407944 (1995-04-01), Goldman
patent: 5550166 (1996-08-01), Ostlund et al.
patent: 5594015 (1997-01-01), Kurtz et al.
patent: 5721230 (1998-02-01), Harris et al.
patent: 5827896 (1998-10-01), Ostlund et al.
patent: 6075005 (2000-06-01), Lurie
patent: 3.203 (1964-01-01), None
patent: 2 320 735 (1977-03-01), None
patent: 1401518 (1975-07-01), None
patent: WO 97 00076 (1977-01-01), None
patent: WO 95/05146 (1995-02-01), None
Califano et al. “Experience with the topical application of spironolactone as an antiandrogen for the treatment of acne.” Clin Ter, 1990 135 (3), pp. 193-199.
Databast in ACS Imsproduct AN 94:25203, Drug Launches, (Jun. 6, 1988).
Bronaugh, R.L. et al., “Methods for in vitro percutaneous absorption studies IV: The flow-through diffusion cell,” J. Pharm. Sci., 74(1):64-7 (Jan. 1985) (abstract only).
Chukwumerije, O. et al., “Studies on the Efficacy of Methyl Esters of n-Alkyl Fatty Acids as Penetration Enhancers,” The J. Invest. Dermatol. 93:349-352 (1989).
DeFronzo, R.A., “Pharmacologic Therapy for Type 2 Diabetes Mellitus,” Annals of Internal Medicine, 131(4):281-303 (Aug. 17, 1999).
Delgado-Charro, M.B., et al., “Percutaneous Penetration and Transdermal Drug Delivery,” Progress in Dermatology (Publ. of Dermatology Foundation, Evanston, IL), 32(4):1-12 (Dec. 1998).
Drug News & Perspectives, The Year's New Drugs Sections, The Year's New Drugs, 1997, 11(1):15 (Jan. 19, 1998).
Dunaif, A, et al., “The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic syndrome,” J. Clin. Endocrinol Metab (United States), 81(9):3299-3306 (Sep. 1996) (abstract only).
Edelman, S.V., “Troglitazone: A New and Unique Oral Anti-Diabetic Agent for the Treatment of Type II Diabetes and the Insulin Resistance Syndrome,” Clinical Diabetes, 60-65 (Mar./Apr. 1997).
Lohray, B.B., et al., “Novel Euglycemic and Hypolipidemic Agents,” J. Med. Chem., 41:1619-1630 (1998).
Nemecz, G., “Saw Palmetto,” U.S. Pharmacist, pp. 97-102 (Jan. 1998).
Osborne, D.W., et al., “Skin Penetration Enhancers Cited in the Technical Literature,” Pharmaceutical Technology Articles, 21(11):58 (Nov. 1997).
Price, V.H., “Drug Therapy—Treatment of Hair Loss,” The New England Journal of Medicine, 341(13):964-973 (Sep. 23, 1999).
Rezulin™ Product Insert, Parke-Davis, 8 pages, Morris Plains, New Jersey, U.S.A. (Jan. 1997).
Rezulin™ Product Insert, Parke-Davis, Morris Plains, New Jersey, U.S.A. (May 1997).
Sawaya, M.E., et al., “Androgenetic Alopecia—New Approved and Unapproved Treatments,” Dermatologic Clinics—New and Emerging Therapies, 18(1):47-61 (Jan. 2000).
Sinclair, R., “Diffuse hair loss,” International Journal of Dermatology, 38(1):8-18 (1999).
Ünlühizarci, K., et al., “The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome,” Clinical Endocrinology, 51:231-236 (1999).
Waterworth, D.M. et al., “Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome,” The Lancet, 349(9057:986-990 (Apr. 5, 1997) (abstract only).
White, Jr., J.R., et al., “Insulin Sensitizers—New Options for Treating Type 2 Diabetes,” U.S. Pharmacists, pp. 124-243 (Nov. 1999).
Krajcik Rozlyn A.
Orentreich Norman
Akin Gump Strauss Hauer & Feld & LLP
Kim Jennifer
Orentreich Foundation for the Advancement of Science, Inc.
Padmanabhan Sreeni
LandOfFree
Methods and compositions for the treatment of alopecia and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of alopecia and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of alopecia and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3545414